Matthew Strobeck - 30 Sep 2021 Form 4 Insider Report for Accelerate Diagnostics, Inc (AXDX)

Role: Director
Signature: /s/ Steven Reichling, attorney-in-fact
Issuer symbol: AXDX
Transactions as of: 30 Sep 2021
Transactions value $: $149,998
Form type: 4
Filing time: 10 Dec 2021, 15:01:08 UTC
Previous filing: 01 Jul 2021
Next filing: 04 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AXDX	Common Stock	Award	$149,998	+19,531	+10.4%	$7.68	206,828	30 Sep 2021	By Birchview Fund, LLC	F1, F2
holding	AXDX	Common Stock						2,025,560	30 Sep 2021	Direct
holding	AXDX	Common Stock						20,000	30 Sep 2021	As UGMA Custodian for minor children

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares purchased by the reporting person from Accelerate Diagnostics, Inc. in connection with the closing of the third and final tranche of an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The third and final tranche of the offering closed on September 30, 2021.
F2	The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Content

Represents shares purchased by the reporting person from Accelerate Diagnostics, Inc. in connection with the closing of the third and final tranche of an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The third and final tranche of the offering closed on September 30, 2021.

The reporting person has sole voting and dispositive power with respect to the shares held by Birchview Fund, LLC in his capacity as the CEO of such entity. The reporting person disclaims beneficial ownership of the shares held by Birchview Fund, LLC except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.